NYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free EW Stock Alerts $86.72 -0.70 (-0.80%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$86.53▼$88.0950-Day Range$84.23▼$95.5652-Week Range$60.57▼$96.12Volume1.99 million shsAverage Volume2.93 million shsMarket Capitalization$52.26 billionP/E Ratio37.38Dividend YieldN/APrice Target$93.27 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Edwards Lifesciences alerts: Email Address Edwards Lifesciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside7.5% Upside$93.27 Price TargetShort InterestHealthy1.62% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.78Based on 19 Articles This WeekInsider TradingSelling Shares$20.38 M Sold Last QuarterProj. Earnings Growth12.27%From $2.77 to $3.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.50 out of 5 starsMedical Sector103rd out of 925 stocksSurgical Appliances & Supplies Industry6th out of 18 stocks 2.3 Analyst's Opinion Consensus RatingEdwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 11 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edwards Lifesciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.62% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently increased by 30.49%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEdwards Lifesciences has received a 54.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Catheters", "Mitral valve repair devices", and "Artificial heart valves" products. See details.Environmental SustainabilityThe Environmental Impact score for Edwards Lifesciences is -0.95. Previous Next 3.2 News and Social Media Coverage News SentimentEdwards Lifesciences has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Edwards Lifesciences this week, compared to 11 articles on an average week.Search InterestOnly 11 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.MarketBeat Follows46 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 2% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold 40,890.77% more of their company's stock than they have bought. Specifically, they have bought $49,729.00 in company stock and sold $20,384,302.00 in company stock.Percentage Held by InsidersOnly 1.29% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Edwards Lifesciences' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 12.27% in the coming year, from $2.77 to $3.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 37.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.22.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 37.38, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 107.56.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 3.65. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 7.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edwards Lifesciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Edwards Lifesciences Stock (NYSE:EW)Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Read More EW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EW Stock News HeadlinesMay 10, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) VP Sells $73,359.20 in StockMay 8, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) CEO Buys $49,729.20 in StockMay 12, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.May 3, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) Director Sells $2,487,999.50 in StockMay 2, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) VP Sells $1,212,624.00 in StockMay 1, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem Sells 7,250 SharesApril 16, 2024 | insidertrades.comThe 5 Stocks Most Sold By Insiders This Year (EW)May 11, 2024 | finance.yahoo.comInvestors in Edwards Lifesciences (NYSE:EW) have seen respectable returns of 50% over the past five yearsMay 12, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.May 9, 2024 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) PT Raised to $101.00May 9, 2024 | seekingalpha.comEdwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)May 8, 2024 | finance.yahoo.comEdwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance DurabilityMay 7, 2024 | markets.businessinsider.comAssessing Edwards Lifesciences: Insights From 11 Financial AnalystsMay 4, 2024 | americanbankingnews.comMichael A. Mussallem Sells 29,350 Shares of Edwards Lifesciences Co. (NYSE:EW) StockMay 4, 2024 | americanbankingnews.comEdwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 3, 2024 | americanbankingnews.comJean-Luc M. Lemercier Sells 14,400 Shares of Edwards Lifesciences Co. (NYSE:EW) StockApril 30, 2024 | finance.yahoo.comEdwards Lifesciences Corporation (NYSE:EW) Q1 2024 Earnings Call TranscriptApril 30, 2024 | markets.businessinsider.comHold Rating Justified for Edwards Lifesciences Amid TAVR Segment UncertaintiesApril 27, 2024 | finance.yahoo.comEdwards Lifesciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsApril 27, 2024 | markets.businessinsider.comAnalysts Are Neutral on These Healthcare Stocks: Edwards Lifesciences (EW), Gilead Sciences (GILD)April 26, 2024 | markets.businessinsider.comStrong Q1 Performance and Positive Market Trends Reinforce Buy Rating for Edwards LifesciencesApril 26, 2024 | finance.yahoo.comEdwards Lifesciences Corp (EW) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth and ...April 26, 2024 | finance.yahoo.comThis 'Critical' Business Helped Edwards Lifesciences Offset Its TAVR MissApril 26, 2024 | benzinga.comDecoding Edwards Lifesciences's Options Activity: What's the Big Picture?April 25, 2024 | investorplace.comEW Stock Earnings: Edwards Lifesciences Beats EPS, Beats Revenue for Q1 2024April 25, 2024 | seekingalpha.comEdwards Lifesciences Non-GAAP EPS of $0.66 beats by $0.02, revenue of $1.6B beats by $30MApril 25, 2024 | washingtonpost.comEdwards Lifesciences: Q1 Earnings SnapshotSee More Headlines Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/25/2024Today5/12/2024Next Earnings (Estimated)7/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees19,800Year Founded1958Price Target and Rating Average Stock Price Target$93.27 High Stock Price Target$107.00 Low Stock Price Target$57.00 Potential Upside/Downside+7.5%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$2.32 Trailing P/E Ratio37.38 Forward P/E Ratio31.31 P/E Growth3.65Net Income$1.40 billion Net Margins23.01% Pretax Margin26.19% Return on Equity22.86% Return on Assets16.52% Debt Debt-to-Equity Ratio0.08 Current Ratio3.75 Quick Ratio2.67 Sales & Book Value Annual Sales$6.00 billion Price / Sales8.70 Cash Flow$2.76 per share Price / Cash Flow31.39 Book Value$11.93 per share Price / Book7.27Miscellaneous Outstanding Shares602,600,000Free Float594,826,000Market Cap$52.26 billion OptionableOptionable Beta1.10 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Bernard J. Zovighian (Age 56)CEO & Director Comp: $2.27MMr. Scott B. Ullem (Age 57)Corporate VP & CFO Comp: $1.35MMr. Donald E. Bobo Jr. (Age 62)Corporate Vice President of Strategy & Corporate Development Comp: $1.27MMr. Larry L. Wood (Age 58)Corporate VP and Group President of TAVR & Surgical Structural Heart Comp: $1.49MDr. Todd J. Brinton FACCM.D., Corporate VP of Advanced Technology & Chief Scientific OfficerMark WilterdingVice President of Investor RelationsMr. Arnold A. Pinkston (Age 65)Corporate VP & General Counsel Mr. Dirksen J. LehmanCorporate Vice President of Public AffairsMs. Christine Z. McCauley (Age 59)Corporate Vice President of Human Resources Mr. Gary I. Sorsher (Age 59)Senior Vice President of Quality & Regulatory Compliance More ExecutivesKey CompetitorsSTERISNYSE:STEIntuitive SurgicalNASDAQ:ISRGZimmer BiometNYSE:ZBHAlign TechnologyNASDAQ:ALGNDexComNASDAQ:DXCMView All CompetitorsInsiders & InstitutionsPatten & Patten Inc. TNSold 5,965 shares on 5/11/2024Ownership: 0.026%Ironwood Investment Counsel LLCSold 427 shares on 5/11/2024Ownership: 0.002%Resurgent Financial Advisors LLCBought 892 shares on 5/11/2024Ownership: 0.001%Bahl & Gaynor Inc.Sold 197 shares on 5/11/2024Ownership: 0.001%Tocqueville Asset Management L.P.Sold 320 shares on 5/10/2024Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions EW Stock Analysis - Frequently Asked Questions Should I buy or sell Edwards Lifesciences stock right now? 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EW shares. View EW analyst ratings or view top-rated stocks. What is Edwards Lifesciences' stock price target for 2024? 18 equities research analysts have issued twelve-month price targets for Edwards Lifesciences' stock. Their EW share price targets range from $57.00 to $107.00. On average, they expect the company's share price to reach $93.27 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price. View analysts price targets for EW or view top-rated stocks among Wall Street analysts. How have EW shares performed in 2024? Edwards Lifesciences' stock was trading at $76.25 at the beginning of the year. Since then, EW shares have increased by 13.7% and is now trading at $86.72. View the best growth stocks for 2024 here. Are investors shorting Edwards Lifesciences? Edwards Lifesciences saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 9,630,000 shares, an increase of 30.5% from the April 15th total of 7,380,000 shares. Based on an average daily trading volume, of 3,550,000 shares, the days-to-cover ratio is presently 2.7 days. Currently, 1.6% of the company's shares are sold short. View Edwards Lifesciences' Short Interest. When is Edwards Lifesciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024. View our EW earnings forecast. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) released its quarterly earnings results on Thursday, April, 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The medical research company earned $1.60 billion during the quarter, compared to analysts' expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a trailing twelve-month return on equity of 22.86%. Read the conference call transcript. What ETFs hold Edwards Lifesciences' stock? ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Honeytree U.S. Equity ETF (BEEZ), Fundamentals First ETF (KNOW), Global X Aging Population ETF (AGNG), Guru Favorite Stocks ETF (GFGF), IQ Winslow Focused Large Cap Growth ETF (IWFG), Tema Cardiovascular and Metabolics ETF (HRTS) and Fidelity Disruptive Medicine ETF (FMED). When did Edwards Lifesciences' stock split? Edwards Lifesciences shares split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were payable to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What guidance has Edwards Lifesciences issued on next quarter's earnings? Edwards Lifesciences issued an update on its second quarter 2024 earnings guidance on Thursday, April, 25th. The company provided earnings per share (EPS) guidance of 0.670-0.710 for the period, compared to the consensus earnings per share estimate of 0.700. The company issued revenue guidance of $1.6 billion-$1.7 billion, compared to the consensus revenue estimate of $1.6 billion. What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO? 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS). Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.79%), Bank of New York Mellon Corp (3.15%), Nordea Investment Management AB (0.35%), Swiss National Bank (0.30%), Raymond James & Associates (0.29%) and Sumitomo Mitsui Trust Holdings Inc. (0.27%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daniel J Lippis, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.Read More This page (NYSE:EW) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICElon to Transform U.S. Economy? Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
